Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 May;39(5):477–483. doi: 10.1111/j.1365-2125.1995.tb04483.x

Antagonism of the effects of clonidine by the alpha 2-adrenoceptor antagonist, fluparoxan.

M A Johnson 1, C P Blackwell 1, J Smith 1
PMCID: PMC1365053  PMID: 7669482

Abstract

1. The effects of fluparoxan, an alpha 2-adrenoceptor antagonist, on the pharmacodynamic changes induced by clonidine were investigated in this placebo-controlled, double-blind, two-period, cross-over study in 16 healthy male volunteers (aged 19 to 44 years). 2. Subjects received either fluparoxan or placebo, twice-daily for 5 1/2 days (11 doses). One hour after the first and last dose of each treatment period, clonidine (200 micrograms) was infused intravenously over 5 min. 3. Indices of clonidine-mediated pharmacodynamic responses (growth hormone secretion, bradycardia, hypotension, xerostomia and sedation) were taken before and after clonidine infusion. Growth hormone secretion was assessed by quantifying serum growth hormone concentrations; sedation was assessed by both visual analogue scales (VAS) and by a visual psychomotor response meter, measuring critical flicker fusion (CFF). 4. The majority of subjects reported minor adverse events such as lethargy, headache and dry mouth following clonidine infusion. All adverse events were likely to be related to clonidine, as they occurred consistently between treatment groups. Fluparoxan has, however, in previous studies been reported to cause headache and light-headedness. 5. Prior to the clonidine infusion, fluparoxan caused small but statistically significant increases in systolic blood pressure (4 mm Hg) and salivary flow (approximately 30%) after both single and repeated doses. A small increase in heart rate (2 beats min-1) was seen after a single dose which was also statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bousquet P., Feldman J., Tibirica E., Bricca G., Greney H., Dontenwill M., Stutzmann J., Belcourt A. Imidazoline receptors. A new concept in central regulation of the arterial blood pressure. Am J Hypertens. 1992 Apr;5(4 Pt 2):47S–50S. [PubMed] [Google Scholar]
  2. Dollery C. T., Davies D. S., Draffan G. H., Dargie H. J., Dean C. R., Reid J. L., Clare R. A., Murray S. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther. 1976 Jan;19(1):11–17. doi: 10.1002/cpt197619111. [DOI] [PubMed] [Google Scholar]
  3. Drew G. M., Gower A. J., Marriott A. S. Alpha 2-adrenoceptors mediate clonidine-induced sedation in the rat. Br J Pharmacol. 1979 Sep;67(1):133–141. [PMC free article] [PubMed] [Google Scholar]
  4. Ernsberger P., Giuliano R., Willette R. N., Reis D. J. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther. 1990 Apr;253(1):408–418. [PubMed] [Google Scholar]
  5. Goldberg M. R., Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983 Sep;35(3):143–180. [PubMed] [Google Scholar]
  6. Halliday C. A., Jones B. J., Skingle M., Walsh D. M., Wise H., Tyers M. B. The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1991 Apr;102(4):887–895. doi: 10.1111/j.1476-5381.1991.tb12272.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamilton C. A. The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther. 1992;54(3):231–248. doi: 10.1016/0163-7258(92)90001-g. [DOI] [PubMed] [Google Scholar]
  8. Hussain J. F., Kendall D. A., Wilson V. G. Species-selective binding of [3H]-idazoxan to alpha 2-adrenoceptors and non-adrenoceptor, imidazoline binding sites in the central nervous system. Br J Pharmacol. 1993 Jul;109(3):831–837. doi: 10.1111/j.1476-5381.1993.tb13650.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lal S., Tolis G., Martin S. B., Brown G. M., Guyda H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone in the serum of normal men. J Clin Endocrinol Metab. 1975 Nov;41(5):827–832. doi: 10.1210/jcem-41-5-827. [DOI] [PubMed] [Google Scholar]
  10. Morley M. J., Bradshaw C. M., Szabadi E. Effects of clonidine and yohimbine on the pupillary light reflex and carbachol-evoked sweating in healthy volunteers. Br J Clin Pharmacol. 1991 Jan;31(1):99–101. doi: 10.1111/j.1365-2125.1991.tb03864.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Müller E. E., Locatelli V., Ghigo E., Cella S. G., Loche S., Pintor C., Camanni F. Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications. Drugs. 1991 Feb;41(2):161–177. doi: 10.2165/00003495-199141020-00002. [DOI] [PubMed] [Google Scholar]
  12. Pineda J., Ugedo L., García-Sevilla J. A. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: possible involvement of imidazoline-preferring receptors. Naunyn Schmiedebergs Arch Pharmacol. 1993 Aug;348(2):134–140. doi: 10.1007/BF00164789. [DOI] [PubMed] [Google Scholar]
  13. Tibiriça E., Feldman J., Mermet C., Gonon F., Bousquet P. An imidazoline-specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharmacol Exp Ther. 1991 Feb;256(2):606–613. [PubMed] [Google Scholar]
  14. Warren J. B., Dollery C. T., Fuller R. W., Williams V. C., Gertz B. J. Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103–109. doi: 10.1038/clpt.1989.113. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES